Management of newly diagnosed epilepsy: A practical guide to monotherapy

Drugs

Volumn 69, Issue 2, 2009, Pages 199-222

  Stein, Michael A ^a   Kanner, Andres M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CONTRACEPTIVE AGENT; CYCLOSPORIN A; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; NEUROLEPTIC AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; THEOPHYLLINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; WARFARIN; ZONISAMIDE;

AGITATION; AGRANULOCYTOSIS; ALGORITHM; ALOPECIA; ANGIONEUROTIC EDEMA; ANHIDROSIS; ANOREXIA; ANXIETY; APLASTIC ANEMIA; BEDTIME DOSAGE; BLEEDING TIME; BLOOD CLOTTING DISORDER; BLOOD DYSCRASIA; BLURRED VISION; BRADYCARDIA; BRAIN DISEASE; CEREBELLUM DEGENERATION; CHEWABLE TABLET; CLEFT LIP; CLEFT PALATE; CLINICAL PROTOCOL; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; COMORBIDITY; CONGENITAL MALFORMATION; CONNECTIVE TISSUE DISEASE; CONTROLLED DRUG RELEASE; COST BENEFIT ANALYSIS; DEPRESSION; DISEASE CLASSIFICATION; DISEASE CONTROL; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CHOICE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG INDICATION; DRUG LABELING; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUPUYTREN CONTRACTURE; ELIXIR; EPILEPSY; EPILEPTIC STATE; FATIGUE; FOOD AND DRUG ADMINISTRATION; FROZEN SHOULDER; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEADACHE; HIRSUTISM; HOSTILITY; HUMAN; HYPERAMMONEMIA; HYPERSENSITIVITY REACTION; HYPONATREMIA; HYPOTENSION; INSOMNIA; IRRITABILITY; LEUKOPENIA; LIVER FAILURE; LIVER NECROSIS; LOADING DRUG DOSE; LUPUS LIKE SYNDROME; MEMORY DISORDER; METABOLIC ACIDOSIS; MONOTHERAPY; MOOD DISORDER; MORNING DOSAGE; NAUSEA; NEPHROLITHIASIS; NEURAL TUBE DEFECT; OVARY POLYCYSTIC DISEASE; PANCREATITIS; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PSEUDOLYMPHOMA; PSYCHOSIS; REMISSION; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUSPENSION; SYRUP; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREMOR; VISUAL FIELD DEFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC;

EID: 60549115283     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969020-00005     Document Type: Review

References (38)

1. Shorvon S. Handbook of epilepsy treatment. 2nd ed. Malden (MA): Blackwell, 2005
2. National Institute for Clinical Excellence. Newer drugs for epilepsy in adults. Technology Appraisal 76, March 2004. London: NICE, 2004
3. Hauser WA, Rich SS, Lee JRJ, et al. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 1998 Feb 12; 338 (7): 429-34
4. Wolf P. International classification of the epilepsies. In: Engel Jr J, Pedley TA, editors. Epilepsy: a comprehensive textbook. Philadelphia (PA): Lippincott-Raven, 1998: 773-7
5. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989 Jul-Aug; 30 (4): 389-99
6. Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002
7. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000 Feb 3; 342 (5): 314-9
8. Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998 Nov; 51 (5): 1256-62
9. Wyllie E, editor. The treatment of epilepsy: principles & practice. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2006
10. Bourgeois B. Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed? Neurology 2000 Dec; 55 (11 Suppl. 3): S11-7
11. Berry DJ, Beran RG, Plunkeft MJ, et al. The absorption of gabapentin following high dose escalation. Seizure 2003 Jan; 12 (1): 28-36
12. Pryor FM, Gidal B, Ramsay RE, et al. Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses. Epilepsia 2001 Feb; 42 (2): 245-50
13. Herzog AG, Drislane FW, Schomer DL. Differential effects of antiepileptic drugs on neuroactive steroids in men with epilepsy. Epilepsia 2006; 47 (11): 1945-8
14. Anderson GS, Pak C, Doane KW, et al. Revised wintertozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. Ann Pharmacother 1997; 31: 279-84
15. Evans WE, Schentag JJ, Jusko WJ, et al., editors. Applied pharmacokinetics. 3rd ed. Vancouver (WA): Applied Therapeutics, 1992
16. Arroyo S, Perucca E. Translating monotherapy trials into clinical practice: a look into the abyss. Epilepsy Behav 2003; 4: 457-63
17. Anderson GD, Gidal BE, Messenheimer JA, et al. Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Res 2002 May; 49 (3): 211-7
18. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurology 2004; 62: 1252-60
19. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007 Mar 24; 369 (9566): 1000-15
20. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007 Mar 24; 369 (9566): 1016-26
21. Hadzic N, Vara R, Raiman J, et al. Old versus new antiepileptic drugs: the SANAD study. Lancet 2007 Jul 28; 370 (9584): 315
22. Shawcross D, Knighton S, Bernal W, et al. Old versus new antiepileptic drugs: the SANAD study. Lancet 2007 Jul 28; 370 (9584): 314-5
23. Cross H, Ferrie C, Lascelles K, et al. Old versus new antiepileptic drugs: the SANAD study. Lancet 2007 Jul 28; 370 (9584): 314
24. Perucca E, Alexandre Jr V, Tomson T. Old versus new antiepileptic drugs: the SANAD study. Lancet 2007 Jul 28; 370 (9584): 313
25. Panayiotopoulos CP. Old versus new antiepileptic drugs: the SANAD study. Lancet 2007 Jul 28; 370 (9584): 313-4
26. Panayiotopoulos CP. Evidence-based epileptology, randomized controlled trials, and SANAD: a critical clinical view. Epilepsia 2007; 48 (7): 1268-74
27. Battino D, Tomson T. Management of epilepsy during pregnancy. Drugs 2007; 67 (18): 2727-46
28. Meador KJ, Pennell PB, Harden CL, et al. Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology 2008 Sep; 71 (14): 1109-17
29. Kluger BM, Meador KJ. Teratogenicity of antiepileptic medications. Semin Neurol 2008; 28 (3): 328-35
30. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005 Mar; 64 (6): 961-5
31. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006 Aug; 67 (3): 407-12
32. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008 May; 70 (22 Pt 2): 2152-8
33. Botto LD, Moore CA, Khoury MJ, et al. Neural-tube defects. N Engl J Med 1999 Nov 11; 341 (20): 1509-19
34. Pennell PB. The importance of monotherapy in pregnancy. Neurology 2003; 60 Suppl. 4: S31-8
35. Wilson RD, Davies G, Desilets V, et al. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2003 Nov; 25 (11): 959-73
36. Adab N. Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful? CNS Drugs 2006; 20 (10): 791-800
37. Leppik IE, Brodie MJ, Saetre ER, et al. Outcomes research: clinical trials in the elderly. Epilepsy Res 2006; (68 Suppl.): S71-6
38. Edwards KR, Sackellares JC, Vuong A, et al. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav 2001 Feb; 2 (1): 28-36